OTCMBMNDF
Market cap23mUSD
Nov 19, Last price
0.31USD
Name
Biomind Labs Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
51.97%
Rev. gr., 5y
%
Revenues
0k
Net income
-1m
L-59.33%
CFO
-780k
L-63.74%
Profile
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 328 | 2,933 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (328) | (2,933) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (2) | 1 | |||||||
Tax Rate | |||||||||
NOPAT | (328) | (2,934) | |||||||
Net income | (1,214) -59.33% | (2,986) -31.09% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 736 | 8 | |||||||
Long-term debt | 8 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 711 | (10) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (780) | (2,151) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 776 | (39) | |||||||
FCF | 122 | (2,607) | |||||||
| Balance | |||||||||
Cash | 24 | 26 | |||||||
Long term investments | |||||||||
Excess cash | 24 | 26 | |||||||
Stockholders' equity | (1,425) | (248) | |||||||
Invested Capital | 736 | 8 | |||||||
ROIC | |||||||||
ROCE | 47.61% | 1,224.69% | |||||||
| EV | |||||||||
Common stock shares outstanding | 74,762 | 74,762 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (313) | (2,889) | |||||||
EV/EBITDA | |||||||||
Interest | 164 | 1 | |||||||
Interest/NOPBT | |||||||||